|
1
|
Gibson CJ, Britton KA, Miller AL and
Loscalzo J: Clinical problem-solving. Out of the blue. N Engl J
Med. 370:1742–1748. 2014.PubMed/NCBI
|
|
2
|
Wu WKK, Lee CW, Cho CH, Fan D, Wu K, Yu J
and Sung JJ: MicroRNA dysregulation in gastric cancer: A new player
enters the game. Oncogene. 29:5761–5771. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Song JH and Meltzer SJ: MicroRNAs in
pathogenesis, diagnosis, and treatment of gastroesophageal cancers.
Gastroenterology. 143:35–47. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin X, Yang M, Xia T and Guo J: Increased
expression of long noncoding RNA ABHD11-AS1 in gastric cancer and
its clinical significance. Med Oncol. 31:422014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shen L, Shan YS, Hu HM, Price TJ, Sirohi
B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, et al: Management of
gastric cancer in Asia: Resource-stratified guidelines. Lancet
Oncol. 14:e535–e547. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chitwood DH and Timmermans MC: Small RNAs
are on the move. Nature. 467:415–419. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morris KV, Chan SW, Jacobsen SE and Looney
DJ: Small interfering RNA-induced transcriptional gene silencing in
human cells. Science. 305:1289–1292. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cai H, Yuan Y, Hao YF, Guo TK, Wei X and
Zhang YM: Plasma microRNAs serve as novel potential biomarkers for
early detection of gastric cancer. Med Oncol. 30:4522013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu X, Luo L, Wu Y, Yu X, Liu Y, Yu X, Zhao
X, Zhang X, Cui L, Ye G, et al: Gastric juice miR-129 as a
potential biomarker for screening gastric cancer. Med Oncol.
30:3652013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Q, Wang Y, Minto AW, Wang J, Shi Q,
Li X and Quigg RJ: MicroRNA-377 is up-regulated and can lead to
increased fibronectin production in diabetic nephropathy. FAsEB J.
22:4126–4135. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wen ZL, Huang W, Feng YL, Wang Y, Liang J,
Cai W, Kang K, Chang D, Zhu P, Milliard RW, et al: MicroRNA-377
regulates angiogenesis by targeting vEGF: Implications for
mesenchymal stem cells based therapy in ischemic heart disease.
Circulation. 128. 2013
|
|
12
|
Li N, Liu Q, Su Q, Wei C, Lan B, Wang J,
Bao G, Yan F, Yu Y, Peng B, et al: Effects of legumain as a
potential prognostic factor on gastric cancers. Med Oncol.
30:6212013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Orditura M, Galizia G, Sforza V,
Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J,
Savastano B, Mabilia A, et al: Treatment of gastric cancer. World J
Gastroenterol. 20:1635–1649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vicentini C, Fassan M, D’Angelo E, Corbo
V, Silvestris N, Nuovo GJ and Scarpa A: Clinical application of
microRNA testing in neuroendocrine tumors of the gastrointestinal
tract. Molecules. 19:2458–2468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Beckman JD, Chen C, Nguyen J, Thayanithy
V, Subramanian V, Steer CJ and Vercellotti GM: Regulation of heme
oxygenase-1 protein expression by miR-377 in combination with
miR-217. J Biol Chem. 286:3194–3202. 2011. View Article : Google Scholar :
|
|
16
|
Zhang R, Luo H, Wang S, Chen W, Chen Z,
Wang HW, Chen Y, Yang J, Zhang X, Wu W, et al: MicroRNA-377
inhibited prolife ration and invasion of human glioblastoma cells
by directly targeting specificity protein 1. Neuro Oncol.
16:1510–1522. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsirimonaki E, Fedonidis C, Pneumaticos
SG, Tragas AA, Michalopoulos I and Mangoura D: PKCε signalling
activates ERK1/2, and regulates aggrecan, ADAMTs5, and miR377 gene
expression in human nucleus pulposus cells. PLoS One. 8:e820452013.
View Article : Google Scholar
|
|
18
|
Bertoli C, Skotheim JM and de Bruin RAM:
Control of cell cycle transcription during G1 and S phases. Nat Rev
Mol Cell Biol. 14:518–528. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Duffy MJ, Synnott NC, McGowan PM, Crown J,
O’Connor D and Gallagher WM: p53 as a target for the treatment of
cancer. Cancer Treat Rev. 40:1153–1160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shetzer Y, Solomon H, Koifman G,
Molchadsky A, Horesh S and Rotter V: The paradigm of mutant
p53-expressing cancer stem cells and drug resistance.
Carcinogenesis. 35:1196–1208. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kubota E, Williamson CT, Ye R, Elegbede A,
Peterson L, Lees-Miller SP and Bebb DG: Low ATM protein expression
and depletion of p53 correlates with olaparib sensitivity in
gastric cancer cell lines. Cell Cycle. 13:2129–2137. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Song MS, Salmena L and Pandolfi PP: The
functions and regulation of the PTEN tumour suppressor. Nat Rev Mol
Cell Biol. 13:283–296. 2012.PubMed/NCBI
|
|
23
|
Hollander MC, Blumenthal GM and Dennis PA:
PTEN loss in the continuum of common cancers, rare syndromes and
mouse models. Nat Rev Cancer. 11:289–301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JFM: The PTEN/PI3K/AKT signalling pathway in
cancer, therapeutic implications. Curr Cancer Drug Targets.
8:187–198. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bjerre C, Vinther L, Belling KC, Würtz SØ,
Yadav R, Lademann U, Rigina O, Do KN, Ditzel HJ, Lykkesfeldt AE, et
al: TIMP1 overexpression mediates resistance of MCF-7 human breast
cancer cells to fulvestrant and down-regulates progesterone
receptor expression. Tumour Biol. 34:3839–3851. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu YC, Chang JT, Liao CT, Kang CJ, Huang
SF, Chen IH, Huang CC, Huang YC, Chen WH, Tsai CY, et al:
OncomiR-196 promotes an invasive phenotype in oral cancer through
the NME4-JNK-TIMP1-MMP signaling pathway. Mol Cancer. 13:2182014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bunatova K, Pesta M, Kulda V, Topolcan O,
Vrzalova J, Sutnar A, Treska V, Pecen L and Liska V: Plasma TIMP1
level is a prognostic factor in patients with liver metastases.
Anticancer Res. 32:4601–4606. 2012.PubMed/NCBI
|
